French medical technology company CorWave announced it has been awarded almost $3.5 million in financing for its R&D program NovaPulse in the Silver Economy category. This is part of phase 2 of France’s Concours Mondial d'Innovation or Worldwide Innovation Challenge.

Women who give birth to infants with congenital heart defects may have an increased risk of cardiovascular hospitalizations later in life, according to new research in the American Heart Association’s journal Circulation.

Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent atrial fibrillation (AF). The Arctic Front Advance Cyroablation System is not approved for treating persistent AF in the United States.

 

The biggest workplace concern for interventional cardiologists and cath lab staff is their daily exposure to ionizing radiation from the angiographic X-ray systems that are central to their procedures. In addition to increased cancer risks and developing cataracts, they are also worried about orthopedic issues caused by wearing heavy radiation protection aprons, which takes a toll on the spine and can lead to chronic back problems.

Abbott today announced the initiation of a clinical trial evaluating long-term outcomes of patients who undergo stent implantation guided by  optical coherence tomography (OCT) compared to angiography. The trial (ILUMIEN IV) is the first large-scale randomized global study using Abbott's OCT imaging in patients with high-risk, complex coronary artery disease. Patients in the study will be randomized to either OCT-guided or traditional angiography to guide placement of one or more Xience everolimus-eluting coronary stents.

https://www.dicardiology.com/channel/vascular-closure-devicesCardiva Medical announced the company received U.S. Food and Drug Administration (FDA) approval for an expanded indication of the Vascade Vascular Closure System. Already approved for use in arterial closure, Vascade is now FDA-approved for use in 5-7F femoral venous closures as well. This expansion creates an opportunity to better treat patients undergoing interventional cardiac catheterization procedures, while also greatly increasing the available market for the device.

University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the first Intrepid transcatheter mitral valve replacement system in the study. Alan Markowitz, M.D., and Guilherme F. Attizzani, M.D., performed the procedure, the first in the state of Ohio.

Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint with a statistically significant reduction in all-cause mortality plus frequency of cardiovascular-related hospitalizations compared to placebo at 30 months. The preliminary safety data showed that tafamidis was generally well tolerated in this population and no new safety signals were identified.1

YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more people better manage their blood pressure. Beginning this spring, more than 100 clinics participating in the Target: BP initiative will be able to refer qualified patients to enroll at no cost in the YMCA’s Blood Pressure Self-Monitoring program.

April 5, 2018 — Medical imaging company Brainomix has attracted £7m ($9.8 million) of investment to bring its artificial intelligence (AI) software for fast stroke diagnosis and treatment to the global healthcare market.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now